Search
Search
Paulo Falabella, MD, PhD
Show Description +
Paulo Falabella, MD, PhD, Medical Director, Ophthalmology, Spark Therapeutics, talks about the significance of the approval of Luxturna (voretigene neparvovec-rzyl), which was the first gene therapy for an inherited disease approved in the United States.
Posted: 7/23/2018
Paulo Falabella, MD, PhD
Paulo Falabella, MD, PhD, Medical Director, Ophthalmology, Spark Therapeutics, talks about the significance of the approval of Luxturna (voretigene neparvovec-rzyl), which was the first gene therapy for an inherited disease approved in the United States.
Posted: 7/23/2018
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of OIS Retina: 2018.
Please log in to leave a comment.